Encouraging results for adjuvant immunotherapy with nivolumab (NIVO) in combination with ipilimumab (IPI) have been reported today at ESMO Congress 2019, according to Caroline Robert, Institut Gustave Roussy, Villejuif, France. The phase II IMMUNED trial showed a significant improvement of recurrence-free survival (FRS) with the combination therapy compared to IPI alone.ESMO Congress 2019 abstract:LBA67 - Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED)
Ipilumab plus nivolumab shows efficacy in resected stage IV melanoma
